CytoTronics, a Boston, MA-based provider of semiconductor-based platforms for discovery in cell biology, raised $13.5M in Series Seed 2 funding.
The Series Seed 2 round was led by new investor LYFE Capital, and existing investor Anzu Partners. New investors including Legend Star, RIT Venture Fund (Rochester Institute of Technology), and Draper Associates also joined the round, with continued support from BoxOne Ventures and other minority financial supporters. The company also announced the appointment of Sameer Rohatgi of LYFE Capital to the Board of Directors.
The company intends to use the funds to build off its early access program and accelerate market entry of their semiconductor-to-live-cell interface for cell biology applications, Pixel™.
Founded by Jeffrey Abbott, CEO, Vince Wu, CTO, and Duane Sword, CBO, CytoTronics enhances cell biology discovery with its semiconductor-based platforms. Its Pixel systems provide live cell insights with single-cell resolution across all cell types. By integrating semiconductors with conventional microplates, Pixel leverages multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering a high level scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications.
FinSMEs
05/09/2024